CV RISK Calculator (Updated for 2023)
2023 Version calculations are adapted to the latest version of the online calculator.
Values automatically entered from known parameters in the patients file.
The UI allows changing parameters.
Note that the updated algorithm does not lend itself to comparing risk pre and post commencement of treatment.
In particular it is not adapted to show risk comparisons for pre and post commencing statin treatment or BP treatment.
It is targeted and making decisions regarding commencement of Lipid-lowering medications and antihypertensive medications for patients not already taking these medications.
Notes regarding the new calculation.
Identify people without known CVD for risk assessment All people aged 45–79 years People with diabetes aged 35–79 years First Nations people aged 30–79
The new CVD risk categories are:
high (≥10% risk over 5 years) intermediate (5 to <10% risk over 5 years) low (<5% risk over 5 years).
Consider optional reclassification
Factors which may refine risk estimates
- CKD (eGFR or uACR) ↑
- Family history ↑
- Severe mental illness ↑
- Ethnicity ↑↓
- Coronary artery calcium score ↑↓
Risk estimates
Represent the chance of having a cardiovascular event in the next 5 years. Newly defined risk categories help target pharmacotherapy to those who will benefit most while stil limiting adverse effects of treatment. Manage risk.
Encourage, support and advise all people
- who smoke to quit,
- to follow a heart-healthy eating pattern
- to reduce their consumption where necessary, in line with national guidelines
- to do regular sustainable physical activity
- to achieve and maintain a healthy weight.
Prescribe pharmacotherapy
For high risk (>=10%) and consider for intermediate risk(5% to <10%)
- BP lowering medications
- lipid-modifying medicines
Cholesterol Management Predictor
To gain insight into the effect of cholesterol management on the risk of cardiovascular disease, the Cholesterol Management Predictor (CMP) can be used. The CMP is a tool that can be used to calculate the effect of cholesterol management
The CMP in DCP is based on a Lancet article referenve Interpretation of the evidence for the efficacy and safety of statin therapy
The calcultor provides the treated LDL and also the risk reduction for up to 5 years of treatment given a starting LDL(non treated) and a starting risk.
It is important to compare with the low risk for age taking into account other factors so this is also provided.